MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer

MET protein (also known as c-Met protein) overexpression (OE) is an emerging clinically relevant biomarker that is targetable with antibody-drug conjugates. c-Met protein's prevalence varies, depending on the different OE thresholds, antibodies, and detection methodologies used. Unlike MET genomic aberrations, MET protein OE is a protein biomarker requiring immunohistochemistry (IHC)-based testing. Herein, we summarize the current evidence on MET protein OE, including prognostic value, heterogeneity, and stability. We also provide key considerations for enabling optimal real-world testing of this IHC-based biomarker.

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2025-11-20
DOI
https://doi.org/10.1038/s41698-025-01144-9
Citations
1
Primary Topic
Liver physiology and pathology
Type
article
Field-Weighted Citation Impact
1.32

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer

Sue Beruti, Mary Beth Beasley, Ignacio I. Wistuba, Peter Ansell et al.
1 citations
npj Precision Oncology
Liver physiology and pathology
1.32
article

MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer

Sue Beruti, Mary Beth Beasley, Ignacio I. Wistuba, Peter Ansell, Peter B. Illei, Kurt A. Schalper, Archana R. Simmons, Mari A. Mino-Kenudson, Ming‐Sound Tsao, Lynette M. Sholl, Michelle Shiller
article en
1 citations

Abstract

MET protein (also known as c-Met protein) overexpression (OE) is an emerging clinically relevant biomarker that is targetable with antibody-drug conjugates. c-Met protein's prevalence varies, depending on the different OE thresholds, antibodies, and detection methodologies used. Unlike MET genomic aberrations, MET protein OE is a protein biomarker requiring immunohistochemistry (IHC)-based testing. Herein, we summarize the current evidence on MET protein OE, including prognostic value, heterogeneity, and stability. We also provide key considerations for enabling optimal real-world testing of this IHC-based biomarker.

npj Precision OncologyVol. 9(1)
Brigham and Women's Hospital (US), University Health Network (CA), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Johns Hopkins University (US), University of Toronto (CA), Johns Hopkins Medicine (US), Baylor University Medical Center (US), Princess Margaret Cancer Centre (CA), AbbVie (United States) (US), Yale University (US), Massachusetts General Hospital (US), Icahn School of Medicine at Mount Sinai (US)
Aptitude Health
Openalex Percentile: Top 14%
Liver physiology and pathology
1.32
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.